ACAD
38.15
-0.08
-0.21%
AEMD
0.19
0.00
-2.31%
APRI
2.41
-0.12
-4.75%
ARNA
4.08
-0.2
-4.67%
ATEC
1.52
+0.02
+1.33%
CFN
60.09
-0.11
-0.18%
CNAT
6.35
+0.15
+2.42%
CRXM
0.2
-0.01
-6.62%
CYTX
1.18
+0.06
+5.27%
DXCM
58.98
-0.68
-1.14%
GNMK
12.72
-0.26
-2.00%
HALO
15.22
0.00
0.00%
ILMN
195.97
+1.91
+0.98%
INNV
0.19
+0.02
+8.89%
INO
7.06
-0.11
-1.53%
ISCO
0.06
0.00
-2.11%
ISIS
68.5
+1.7
+2.54%
LGND
66.69
+3.11
+4.89%
LPTN
2.95
+0.01
+0.34%
MBVX
0.93
+0.03
+3.33%
MEIP
5.7
+0.04
+0.71%
MNOV
3.63
+0.09
+2.54%
MRTX
23.66
-0.53
-2.19%
MSTX
0.52
-0.01
-0.96%
NBIX
40.65
+0.22
+0.54%
NUVA
44.21
-0.46
-1.03%
ONCS
0.37
+0.01
+3.04%
ONVO
5.74
-0.01
-0.17%
OREX
7.73
+1.94
+33.44%
OTIC
36.62
+0.24
+0.66%
QDEL
25.82
-0.59
-2.23%
RCPT
125.36
-1.73
-1.36%
RGLS
18.17
-0.4
-2.15%
RMD
64.44
-0.32
-0.49%
SCIE
0.03
0.00
0.00%
SPHS
0.68
-0.06
-8.43%
SRNE
13.25
+0.38
+2.95%
TROV
6.28
+0.23
+3.80%
VICL
0.99
+0.00
+0.01%
VOLC
17.99
0.00
0.00%
ZGNX
1.68
-0.01
-0.59%
Home » Archive by Category

Syndication

Arena Pharmaceuticals, Inc. Announces Marketing Approval In South Korea Of BELVIQ (lorcaserin HCl) For Weight Management

February 2, 2015 – 5:00 pm

SAN DIEGO, Feb. 3, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ (lorcaserin HCl) for marketing for…

Samsung Corporation Premium Ultrasound System Enhances Fetal Heart Imaging And Diagnosis With Advanced 5D Applications

February 2, 2015 – 5:00 pm

SAN DIEGO–(BUSINESS WIRE)–Samsung Electronics America, Inc., a subsidiary of Samsung Electronics Co. Ltd, today introduced the Samsung WS80A with Elite performance package, its flagship ultrasound product for womens healthcare designed to streamline …

Isis Pharmaceuticals, Inc.’s Diabetes Drug Effective in Phase 2 Study

February 2, 2015 – 5:00 pm

Isis Reports Data From Phase 2 Study Of ISIS-PTP1B Rx In Patients With Type 2 DiabetesCARLSBAD, Calif., Feb. 3, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today top-line results from a Phase 2 study of ISIS-PTP1BRx in pati…

Auspex Pharmaceuticals Completes Enrollment In A Pivotal Clinical Trial Of SD-809 In Tardive Dyskinesia

February 2, 2015 – 5:00 pm

LA JOLLA, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) — Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that it …

Regulus Therapeutics, Inc. To Present At Two Upcoming Investor Conferences

February 2, 2015 – 5:00 pm

LA JOLLA, Calif., Feb. 2, 2015 /PRNewswire/ –Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that

Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus FOLFOX In Advanced Gastrointestinal Malignancies

February 2, 2015 – 5:00 pm

SAN DIEGO, Feb. 3, 2015 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) for the treatment of adv…

Celladon Corporation To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference

February 2, 2015 – 5:00 pm

SAN DIEGO, Feb. 3, 2015 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that the Company will provide a corporate update and overview at the BIO CEO &amp…

Imprimis Pharmaceuticals And Announce Positive Findings Of Evaluation Of LessDrops Combination Eye Drop Formulations Following LASIK Surgery

February 2, 2015 – 5:00 pm

SAN DIEGO and CLEVELAND, Feb. 3, 2015 /PRNewswire/ –Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, and Cleveland Eye Clinic, today anno…

Mast TherapeuticsTo Present At 17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference On February 9th

February 2, 2015 – 5:00 pm

SAN DIEGO, Feb. 3, 2015 /PRNewswire/ –Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company’s Chief Executive Officer, Brian M. Culley

Imprimis Pharmaceuticals Announces Two Key Leadership Promotions

February 2, 2015 – 5:00 pm

SAN DIEGO, Feb. 2, 2015 /PRNewswire/ –Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, today announced that it has promoted